Natera Publishes Clinical Validation of Latitude™ Tissue-Free MRD Test in Colorectal Cancer

Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced the publication in npj ...
Detroit News

Dr. Roach: New cell-free DNA testing not recommended for p. vera patient

Dear Dr. Roach: I am 85 and healthy apart from polycythemia vera, for which I take aspirin. I was interested in the new blood test for cancer. Is it worthwhile? Dear M.N.: When screening patients for ...
Hosted on MSN

Cell-free DNA could detect adverse events from immunotherapy

A noninvasive blood test to detect genetic material shed by tumors may help clinicians identify adverse events related to treatment with immune checkpoint inhibitor drugs, investigators at the Johns ...
Business Wire

Natera Announces Broad Clinical Launch of Ultra-Sensitive Signatera ™ Genome MRD Test

AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and genetic testing, today announced that its ultra-sensitive Signatera Genome assay is now broadly ...
Medscape

DNA Test Outshines PET for Lymphoma Prognosis

Circulating tumor DNA (ctDNA) minimal residual disease (MRD) assessment at treatment completion provides superior prognostic accuracy compared with PET in large B-cell lymphoma. The CLARITY assay ...